Literature DB >> 30602199

Apolipoprotein C-III Strongly Correlates with Activated Factor VII-Anti-Thrombin Complex: An Additional Link between Plasma Lipids and Coagulation.

Nicola Martinelli1, Marcello Baroni2, Annalisa Castagna1, Barbara Lunghi2, Filippo Stefanoni1, Federica Tosi1, Jacopo Croce1, Silvia Udali1, Barry Woodhams3, Domenico Girelli1, Francesco Bernardi2, Oliviero Olivieri1.   

Abstract

Activated factor VII-anti-thrombin (FVIIa-AT) complex is a potential biomarker of pro-thrombotic diathesis reflecting FVIIa-tissue factor (TF) interaction and has been associated with mortality in patients with coronary artery disease (CAD). Previous data indicated plasma lipids as predictors of FVIIa-AT variability, and plasma lipoproteins as potential stimulators of the coagulation cascade. Our aim was to evaluate the relationships between FVIIa-AT plasma concentration and a broad apolipoprotein profile (including ApoA-I, ApoB, ApoC-III and ApoE). Within the framework of the observational Verona Heart Study, we selected 666 subjects (131 CAD-free and 535 CAD, 75.4% males, mean age: 61.1 ± 10.9 years) not taking anticoagulant drugs and for whom plasma samples were available for both FVIIa-AT assay and a complete lipid profile. Plasma concentration of FVIIa-AT levels significantly and directly correlated with total and high-density lipoprotein cholesterol, triglycerides, ApoA-I, ApoC-III and ApoE levels. ApoC-III showed the strongest correlation (R = 0.235, p = 7.7 × 10-10), confirmed in all the sub-group analyses (males/females and CAD/CAD-free). Only ApoC-III remained associated with FVIIa-AT plasma concentration, even after adjustment for sex, age, CAD diagnosis, body mass index, renal function, smoking status, lipid-lowering therapies and FVIIa levels. The APOC3 gene locus-tagging polymorphism rs964184, previously linked with cardiovascular risk and plasma lipids by genome-wide association studies, was associated with both ApoC-III and FVIIa-AT plasma concentration. Our results indicate a strong association between ApoC-III and FVIIa-AT levels, thereby suggesting that an increased ApoC-III concentration may identify subjects with a pro-thrombotic diathesis characterized by an enhanced TF-FVIIa interaction and activity. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30602199     DOI: 10.1055/s-0038-1676817

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

1.  Guanidinylated Apolipoprotein C3 (ApoC3) Associates with Kidney and Vascular Injury.

Authors:  Stefan J Schunk; Juliane Hermann; Tamim Sarakpi; Sarah Triem; Michaela Lellig; Eunsil Hahm; Stephen Zewinger; David Schmit; Ellen Becker; Julia Möllmann; Michael Lehrke; Rafael Kramann; Peter Boor; Peter Lipp; Ulrich Laufs; Winfried März; Jochen Reiser; Joachim Jankowski; Danilo Fliser; Thimoteus Speer; Vera Jankowski
Journal:  J Am Soc Nephrol       Date:  2021-09-29       Impact factor: 10.121

2.  Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study.

Authors:  Julius L Katzmann; Christian M Werner; Tatjana Stojakovic; Winfried März; Hubert Scharnagl; Ulrich Laufs
Journal:  Lipids Health Dis       Date:  2020-05-30       Impact factor: 3.876

3.  High Plasma Concentration of Apolipoprotein C-III Confers an Increased Risk of Cerebral Ischemic Events on Cardiovascular Patients Anticoagulated With Warfarin.

Authors:  Oliviero Olivieri; Gianni Turcato; Manuel Cappellari; Filippo Stefanoni; Nicola Osti; Francesca Pizzolo; Simonetta Friso; Antonella Bassi; Annalisa Castagna; Nicola Martinelli
Journal:  Front Cardiovasc Med       Date:  2022-02-04

Review 4.  The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans.

Authors:  Jan Borén; Chris J Packard; Marja-Riitta Taskinen
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-28       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.